EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CBD-rich Cannabis Sativa on core and comorbid symptoms of autism spectrum disorder: a prospective observational study

Alysson Madruga Liz, Rafael Mariano Bitencourt, Paulo César Trevisol Bittencourt, Raquel Alberti, Kelser de Souza Kock

Arquivos de Neuro-Psiquiatria · 01.09.2023 · 81 (S 01 S 01) · S1-S96

DOI: 10.1055/s-0043-1774486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.09.2023. Verfasst von Alysson Madruga Liz und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autism spectrum disorder (ASD) is a heterogeneous condition of early neurodevelopment defined by deficits in social interaction and social communication, along with repetitive patterns of behavior, interests or activities. The pathogenesis of ASD is incompletely understood, although there is general agreement that it is caused by genetic factors that modify brain development, specifically neural connectivity. This process is likely related to the role that microglia can play in controlling synaptic pruning and neuroinflammation. The Endocannabinoid System exerts control over microglial activity and therefore offers a possibility of intervention in ASD. Preclinical studies indicate that anandamide administration induces an increase in IL-10 (anti-inflammatory cytokine) production by microglia cells. Furthermore, stimulation of CB2R leads to a protective phenotype in microglia, responsible for decreased secretion of IL-1.

Objective

There is no established pharmacological treatment for the core symptoms of ASD and the psychotropic drugs used in adjuvant symptoms have limited effectiveness and expressive adverse effects. In this context, new medications are needed to control ASD-related symptoms and to promote quality of life for patients and their families.

Methods

This observational study was designed to evaluate the effects of CBD-rich Cannabis s. oil on core and comorbid symptoms of ASD over 24 weeks, simultaneously with the withdrawal of commonly used psychotropic drugs. The primary outcomes assessed the core symptoms of ASD. The secondary endpoints assessed neuropsychiatric manifestations and adverse effects. For all participants, a fixed dose of 5 drops of the cannabis oil distributed 3 times daily was started (CBD: 18.8 mg/d; THC: 1.3 mg/d).

Results

27 participants completed the follow-up (mean±SD age, 7.2±2.9 years). There was significant (p

Zitieren

APA

Liz, A. M., Bitencourt, R. M., Bittencourt, P. C. T., Alberti, R., & Kock, K. D. S. (2023). CBD-rich Cannabis Sativa on core and comorbid symptoms of autism spectrum disorder: a prospective observational study. Arquivos de Neuro-Psiquiatria, 81(S 01 S 01), S1-S96. https://doi.org/10.1055/s-0043-1774486

Vancouver

Liz AM, Bitencourt RM, Bittencourt PCT, Alberti R, Kock KDS. CBD-rich Cannabis Sativa on core and comorbid symptoms of autism spectrum disorder: a prospective observational study. Arquivos de Neuro-Psiquiatria. 2023;81(S 01 S 01):S1-S96. doi:10.1055/s-0043-1774486

BibTeX
@article{Liz2023,
  author = {Liz, Alysson Madruga and Bitencourt, Rafael Mariano and Bittencourt, Paulo César Trevisol and Alberti, Raquel and Kock, Kelser de Souza},
  title = {CBD-rich Cannabis Sativa on core and comorbid symptoms of autism spectrum disorder: a prospective observational study},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2023},
  volume = {81},
  number = {S 01 S 01},
  pages = {S1--S96},
  doi = {10.1055/s-0043-1774486}
}
Kostenlos starten →